BioSpace News Archive

Wave Life Sciences Ltd. (Nasdaq: WVE) today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 3:00 p.m. PT / 6:00 p.m. ET.

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, announced clearance by the U.S. Food and Drug Administration (FDA) for the Company’s 510(k) premarket notification submission to market Pure Impact™ utilizing PlyoPulse™ EMS (“electromagnetic stimulation”) technology in the United States.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 2:15 p.m. PT in San Francisco.

Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.

Turn Biotechnologies announced the expansion of its eTurna™ delivery platform that is expected to overcome the greatest challenge to breakthrough therapies: The safe and efficient targeting of specific organs and cells.

Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. as its wholly-owned North American subsidiary.

T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to expand the use of its FDA-cleared T2Candida® Panel to include pediatric testing.

Abbott will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens.

AbelZeta Pharma, Inc. today announced the formation of a Scientific Advisory Board (the “SAB”) to advance its cell therapies for the treatment of inflammatory and immunological diseases.

DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 10, 2024, at 7:30 am PT (10:30 am ET).